Research programme: serotonin 2A receptor inverse agonists - Arena Pharmaceuticals

Drug Profile

Research programme: serotonin 2A receptor inverse agonists - Arena Pharmaceuticals

Alternative Names: AR 116081; AR 116082

Latest Information Update: 21 Apr 2011

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Tripos
  • Class Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Schizophrenia; Sleep disorders

Most Recent Events

  • 10 Apr 2008 Pharmacodynamics data presented at the 235th American Chemical Society National Meeting (235th-ACS-2008)
  • 20 Jul 2007 APD 791 has entered clinical development
  • 22 Feb 2006 Preclinical trials in Stroke in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top